M Pharmaceutical develops female sexual dysfunction drug
January 14, 2017M Pharmaceutical will continue develop a patented topical drug product for the treatment of female sexual dysfunction (FSD), as part of its planned acquisition of 40 J’s.
This M Pharma’s drug will focus on women with orgasm and arousal difficulties. The CEO of M Pharmaceutical USA commented: “Unlike the other two drugs approved by the US FDA to treat FSD, our topical drug product would focus on women with orgasm and arousal difficulties.”
The M Pharma’s CEO further said that Valeant’s Addyi, recently acquired from Sprout Pharmaceuticals, is indicated only for HSDD (desire disorder) with a number of FDA imposed prescription and marketing restrictions. Intrarosa, by Endoceutics, is indicated for dyspareunia (pain with intercourse) with certain prescribing restrictions.
“Our proposed treatment is topical, local and non-systemic, with daily and on demand use, while being non-hormonal and not a central nervous system drug.”
M Pharma expects FDA’s approval, based on the safety profiles of the API and excipients in the drug product.
Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to its recent acquisition of C-103, a reformulation of orlistat from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights. The Company has also recently acquired an FDA cleared fertility product branded as ToConceive that represents its first offering in the women’s health field.
